539644

UCN-01

A cell-permeable Staurosporine derived anticancer agent that reversibly and ATP-competitively inhibits several protein kinases.

• Synonim(y): UCN-01, 7-Hydroxystaurosporine, Staurosporine, 7β-Hydroxy, Streptomyces sp., Chk1 Inhibitor VI, Chk2 Inhibitor V
• Wzór empiryczny (zapis Hilla): C₂₈H₂₆N₄O₄
• Numer CAS: 112953-11-4
• Masa cząsteczkowa: 482.53
• MDL number: MFCD26960886
• UNSPSC Code: 12352200
• NACRES: NA.77
• Assay: ≥95% (HPLC)
• Form: solid
• Storage condition: OK to freeze, protect from light

Właściwości

• Quality Segment: 100
• assay: ≥95% (HPLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, protect from light
• color: tan, white to beige
• solubility: ethanol: 1 mg/mL, DMSO: 5 mg/mL
• shipped in: ambient
• storage temp.: 2-8°C
• SMILES string: [n]21c3c4[n](c6c(c4c7c(c3c8c2cccc8)[C@H](NC7=O)O)cccc6)[C@@H]5O[C@]1([C@@H]([C@@H](C5)NC)OC)C
• InChI: 1S/C28H26N4O4/c1-28-25(35-3)15(29-2)12-18(36-28)31-16-10-6-4-8-13(16)19-21-22(27(34)30-26(21)33)20-14-9-5-7-11-17(14)32(28)24(20)23(19)31/h4-11,15,18,25,27,29,34H,12H2,1-3H3,(H,30,33)/t15-,18-,25-,27-,28+/m1/s1
• InChI key: PBCZSGKMGDDXIJ-HQCWYSJUSA-N

Opis

General description

A cell-permeable Staurosporine (Cat. No. 569397) derived anticancer agent that reversibly and ATP-competitively inhibits several protein kinases (IC₅₀ = 29 nM, 34 nM, 30 nM, 590 nM and 530 nM for PKCα, PKCβ, PKCγ, PKCδ and PKCε; IC₅₀ = 7 nM, 27 nM, 50 nM, 50 nM, 150 nM and 1.04 M for Chk1, Cdc25C-associated protein kinase 1, Cdk1, PAK4, Cdk5/p25 and Chk2; IC₅₀ = 33 nM, 50 nM, 95 nM, 500 nM, 500 nM and 1.0 M for PDK1, lck, MAPKAP kinase-2, Akt, GSK-3β and PKA, respectively). At higher concentrations (>15 M), affects the activities of Src, PIM-1, CKII, DNA-PK, ErK1, ILK-1 and MAPKK1). Reported to suppress thymidylate synthase expression, induce apoptosis with caspase activation, and sensitize tumor cells to a range of DNA-damaging agents.

Biochem/physiol Actions

Cell permeable: yes

IC50 = 29 nM, 34 nM, 30 nM, 590 nM, 530 nM, 7 nM, 27 nM, 50 nM, 50 nM, 150 nM, 1.04 µM, 33 nM, 50 nM, 95 nM, 500 nM, 500 nM and 1.0 µM, respectively for primary targets in the order listed

Primary Target
PKCα, PKCβ, PKCγ, PKCδ PKCε, Chk1, Cdc25C-associated protein kinase 1, Cdk1, PAK4, Cdk5/p25 and Chk2, PDK1, lck, MAPKAP kinase-2, Akt, GSK-3β and PKA

Product competes with ATP.

Reversible: yes

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Reinhardt, H.C., et al. 2007. Cancer Cell11, 175.
Jiang, X., et al. 2004. Mol. Cancer Ther.3, 1221.
Sato, S., et al. 2002. Oncogene21, 1727.
Patel, V., et al. 2002. Clin. Cancer Res.8, 3549.
Leclerc, S., et al. 2001. J. Biol. Chem.276, 251.
Busby, E.C., et al. 2000. Cancer Res.60, 2108.
Hsueh, C.T., et al. 1998. Clin. Cancer Res.4, 2201.
Akiyama, T., et al. 1997. Cancer Res.57, 1495.
Seynaeve, C.M., et al. 1994. Mol. Pharmacol.45, 1207.
Takahashi, I., et al. 1987, J. Antibiot.40, 1782.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• Klasa składowania: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable